BTBP(SH:600161) Ge Long Hui A P P·2025-12-04 09:12Core Viewpoint - Tian Tan Biological Products Co., Ltd. has announced the successful completion of Phase III clinical trials for its "Prothrombin Complex Concentrate," indicating a significant advancement in treatment options for patients with various coagulation factor deficiencies [1] Group 1: Product Information - The product, Prothrombin Complex Concentrate, is primarily indicated for the treatment of congenital and acquired deficiencies of coagulation factors II, VII, IX, and X [1] - Specific indications include treatment for conditions such as Hemophilia B, anticoagulant overdose, vitamin K deficiency, liver disease-related coagulopathy, and surgical patients with prolonged prothrombin time [1] Group 2: Clinical Trial Results - Clinical trial results demonstrate that the infusion of the Prothrombin Complex Concentrate significantly increases the levels of coagulation factors II, VII, IX, and X in patients with Hemophilia B, thereby improving their coagulation function and alleviating bleeding symptoms [1] - Safety analysis indicates that the drug has a good safety profile during clinical application for patients with Hemophilia B [1]